(CercleFinance.com) – Pfizer announced today that it has completed the acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of novel antiviral treatments targeting respiratory syncytial virus (RSV). ).
ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus. Sisunatovir has received Fast Track designation from the US Food and Drug Administration (FDA).
The lead candidate for this program is currently in phase 1 clinical development.
“This acquisition further demonstrates our commitment to advancing cutting-edge science – both through our in-house expertise and through our work with leading innovative companies – with the goal of delivering new breakthroughs to patients suffering from diseases infections,” said Mikael Dolsten, MD, Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical, Pfizer.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
